Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity

Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the 11 most popular AI penny stocks to buy now.

On February 17, Myles Minter from William Blair upgraded his rating on Neumora Therapeutics Inc. (NASDAQ:NMRA) from Market Perform to Outperform. The analyst also shared a net present value figure of $7.62 per share for the stock’s valuation.

Minter anticipated a rising success probability of 35% for the company’s NMRA-511, which is utilized in Alzheimer’s disease agitation. This came after data revealed by Neumora Therapeutics Inc. (NASDAQ:NMRA) on the Phase Ib study.

The analyst noted that the study revealed some meaningful cuts in the Cohen-Mansfield Agitation Inventory endpoint. He maintains his views on Alzheimer’s disease agitation, which he sees as a massive opportunity within the market. Moreover, based on some conservative underlying assumptions, Minter has projected peak U.S. sales figures of around $1.8 billion for NMRA-511.

Neumora Therapeutics Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company that specializes in developing targeted therapies for complex neuropsychiatric and neurodegenerative conditions. These range from major depressive disorder to Alzheimer’s and Parkinson’s. By focusing on the science of the central nervous system, they aim to provide life-changing solutions for those facing mental health and neurological challenges.

While we acknowledge the potential of NMRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.